Following the success of NexGard Spectra, Boehringer Ingelheim Animal Health (BIAH) developed the first isoxazoline designed specifically for cats – esafoxolaner – and launched NexGard COMBO, the next generation of feline parasiticide from BIAH. As a result of NexGard COMBO, BROADLINE has been discontinued.
BROADLINE is a spot-on solution for cats that contains fipronil, (S)-methoprene, eprinomectin and praziquantel and is licensed for use in cats with or at risk from mixed infestations by fleas, ticks, roundworms and tapeworms.
NexGard COMBO also contains eprinomectin and praziquantel for worming, as found in BROADLINE.
Both products are licensed for use in cats with or at risk from mixed infestations by cestodes, nematodes and the treatment of ear mites in breeding, pregnant, and lactating queens.
“We’re dedicated to helping protect pets from parasitic disease, and NexGard COMBO for cats advances our mission to create a future where no pets suffer from parasitic infections,” says Whit Cothern, DVM, executive director of veterinary professional services at Boehringer Ingelheim Animal Health.
Practices can order NexGard COMBO today via their usual wholesaler or speak to their BIAH Territory Manager.
Practices are also encouraged to learn more about NexGard COMBO by watching the explainer video available on the Boehringer Academy website.
